Online inquiry

IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6905MR)

This product GTTS-WQ6905MR is a type of mRNA modified with Pseudo-UTP, which ecodes the monoclonal antibody that targets Alkaline phosphatase substitute gene. The antibody can be applied in Hypophosphatasia (HPP) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000478.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 249
UniProt ID P05186
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6905MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12800MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ7336MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA FPA-150
GTTS-WQ4926MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ4193MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB019
GTTS-WQ5383MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ227MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ12348MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA N63Ab
GTTS-WQ9859MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA K7153A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW